Updated just now · Live
Stock analysis, price data, and AI-powered insights for Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for MNPR.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). MNPR Stock Intelligence Report. [stoxpulse.com/stocks/mnpr]
Disclaimer: The information on this page about Monopar Therapeutics Inc (MNPR) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Monopar Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Monopar Therapeutics Inc. Presents Phase 3 Data Sh...
1d ago
Reported Sunday, Monopar Presents Phase 3 Data At ...
1d ago
StoxPulse AI results for MNPR: Pulse Score 51.5/100. Primary sentiment trends from 3 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$366.1M
P/E Ratio
—
EPS
—
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic Symptoms
Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson Disease
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026